UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`UNI'I'ED STATES DEPARTMENT OF (TUMAIERCE
`United Slales Patcnl and Trademark Office
`Atltllcss:
`l‘OW’IISSIUNlZR ["{lR FAT] 31‘“ 5
`1J D. Em I450
`Ales auldrin. Virginia 223 I .1- | 461'!
`WWW ”51:10.31“;
`
` APPLICA'I‘ION NUMBER PATL'LN'I' NUMBER GROUP ART UNI'I' REQL'ES'J' 1D
`1 5![1 1 ISO?)
`103765 35
`1629
`102 656
`
`
`
`
`
`
`
`PAIR Correspondence Address/Fee Address Change
`
`The Following fields have been changed to Customer Number 166905 on UUUBIEDZO via Private PAIR in View
`of the certification copied below that authorized the change.
`
`0 Correspondence Address
`
`The address for Customer Number 166905 is:
`166905
`
`lI'olcy & Lardner LLI‘
`3000 K Street NW.
`Suite 600
`
`Washinglom DC 20007 -5 l 09
`
`I certify, in accordance with 37 CFR l.4(d)(4) that I am:
`
`An attorney or Agent of Record registered to practice before the Patent and Trademark Office who has been given
`power of attorney in this application
`
`Stephen B mm,
`
`Liquidia's Exhibit 1016
`Page 1
`
`Liquidia's Exhibit 1016
`Page 1
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`UNITED STATES DEPARTMENT OF mM‘MERCE
`United States Patent and Trademark Office
`Atldlclm: COMMISSIONER l-‘CIR PA'I'HN'I'S
`PI]. link 1450
`Alexandria, Virginia 213134-150
`WWW "slump“
`
`:\.F‘1'-"I.]i.‘A'l'Ii.)N NO.
`1551 'Ii DATE
`PA'I'IEN'I'ND,
`A'i"I‘()RNlZ\' DOCKET NO.
`(DNI'IKMATIUN NO.
`
`1 5m: 1.999
`03;] 31'2019
`ms ItiSES
`uses: 3- : 6'39
`4902
`
`22423
`
`I590
`
`roman I t!
`
`FOLEY & LARDNER LLP
`3000 K S’l‘Rl—Ili’l‘ NW.
`SUITE 600
`WASHINGTON. DC 20007-5109
`
`ISSUE NOTIFICATION
`
`The. projected patent number and issue date are specified above.
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent TeiTn Adjustment is 0 day(s). Any patent to issue from the above—identified application will include
`an indication of the adjustment on the front page.
`
`If :1 Continued Prosecution Application (CPA) was filed in the above—identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (httpa’fpair.uspto.gov,}.
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office
`of Patent Legal Administration at (571)-333-7702. Questions relating to issue and publication fee payments
`should be directed to the Application Assistance Unit {AAU) of the Office of Data Management {ODM} at
`(571)-272-4200.
`
`APPLICANTi s)
`
`( Please see PAIR WEB site htlp:ii}mir.usplo.gov for additional applicants):
`
`Horst OLSCl—IEWSKI, Graz, AUSTRIA;
`
`llniled Therapeutics Corporation, Silver Spring, MD:
`Robert ROSCIGNO, Chapel Hill, NC;
`Lewis .I. RUBIN, La] 01111, CA;
`Thomas SCHMEHL, Giessen, GERMANY, Deceased;
`Werner SEEGER, Giessen, GERMANY;
`
`Carl S'I‘ERRI'I‘T, Weybridge, UNITED KINGDOM:
`Robert VOSWINCKEL, Giessen, GERMANY;
`
`The United States represents the largest. most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about Why the USA is the best country in
`the World to develop technology, manufacture products, and grow your business, visit SelectU SA.gov.
`1R10'3 (Rev. [0109)
`
`Liquidia's Exhibit 1016
`Page 2
`
`Liquidia's Exhibit 1016
`Page 2
`
`

`

` {wtm‘raK‘EUNI'I‘ED Snares PA'I‘ENT AND TmuaMARr-z OFFICE
`
`UNITE” ST'VI‘FS I]I‘:P-\ “TM I‘N'I‘ I'JI" [TIM M I‘IIII‘I‘:
`United States Patent and Trude-mark [.lfl'iwa
`.1!links-5. 1" 'JI\I\-I If‘uEIIl'J.I“(L-II F'IR FATE:”151?
`PL Bax I i‘U
`.-\]‘ mutdmr. \‘Iflflllfll 12 3|i- l-I'.|(J
`anvil.-.TJIi1 gm
`
`a\.F‘W.II.'.'J\'I'IUN
`' n
`T
`_
`‘
`GRF ARI'
`TOT CLA[MS IND CL.\IMS
`'NU'A'IBHd
`3'? I re] DATE
`UNIT
`FI]. FEE. REC'D
`ATTYDOCKET NO
`lfil’Ul 1,999
`DZIOIJ‘ZUII’)
`I629
`l?40
`030618-1639
`CONFIRMATION no.14902
`CORRECTED FILING RECEIPT
`
`22428
`
`5355;“ STLFI‘EF‘EDT“NEIIFLP
`
`SUITE 600
`
`WASHINGTON, DC 20007—5109
`
`llflllllIilllllflllllllfllllfitlmilllillmlulllIIIIIIIIIIIIIIIII
`
`Date Mailed: 07J15f2019
`
`Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for
`examination in due course. Applicant will be notified as to the results of the examination. Any correspondence
`concerning the application must include the following identification information: the US. APPLICATION NUMBER.
`FILING DATE, NAME OF FIRST INVENTOR. and TITLE OF INVENTION. Fees transmitted by check or draft are
`subject to collection.
`
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt. please
`submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes
`with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or
`other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt
`with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another
`Filing Receipt incorporating the requested corrections provided that the request is grantable.
`
`lnventor(s)
`
`Horst OLSCHEWSKI, Graz, AUSTRIA;
`Robert ROSCIGNO, Chapel Hill. NC;
`Lewis J. RUBIN, LaJoIla, GA;
`Thomas SCHMEHL, Giessen, GERMANY, Deceased;
`Werner SEEGER. Giessen. GERMANY;
`
`Carl STERRITT. Weybridge. UNITED KINGDOM;
`Robert VOSWINCKEL, Giessen, GERMANY;
`
`Applicanfls)
`
`United Therapeutics Corporation, Silver Spring. MD:
`Assignment For Published Patent Application
`United Therapeutics Corporation, Silver Spring, MD
`
`Power of Attorney: The patent practitioners associated with Customer Number 22428
`
`Domestic Priority data as claimed by applicant
`This application is a DIV of 13J469,854 05H 1J2012 PAT 9339507
`which is a DIV of 12591200 11r12r2009 PAT 9358240
`which is a CON of 112748205 05J14J2007 ABN
`which claims benefit of 60J800.016 05J15J2006
`
`Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution
`Highway program at the USPTO. Please see httpflwwwusptogov for more information.) - None.
`
`page 1 of 4
`
`Liquidia's Exhibit 1016
`Page 3
`
`Liquidia's Exhibit 1016
`Page 3
`
`

`

`Foreign application information must be provided in an Appiication Data Sheet in order to constitute a oiaim to
`foreign priority. See 3 7 CFFl i .55 and 1.76.
`
`Permission to Access Application via Priority Document Exchange: Yes
`
`Permission to Access Search Results: Yes
`
`Applicant may provide or rescind an authorization for access using Form PTOiSBiSQ or Form PTOiSBiSQ as
`appropriate.
`
`"Required, Foreign Filing License Granted: 0211722016
`
`The country code and number of your priority application. to be used for filing abroad under the Paris Convention.
`is US 15/011,999
`
`Projected Publication Date: Not Applicable
`
`Non-Publication Request: No
`
`Early Publication Request: No
`Title
`
`TREPROSTINIL ADMINISTRATION BY INHALATION
`
`Preliminary Class
`
`514
`
`Statement under 37 CFFI 1.55 or 1.73 for AIA (First Inventor to File) Transition Applications: No
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country. an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries. but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law. and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must
`issue a license before applicants can apply fora patent in a foreign country. The filing of a US. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet. "General Information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timefran'les and deadlines for filing foreign
`page 2 of 4
`
`Liquidia's Exhibit 1016
`Page 4
`
`Liquidia's Exhibit 1016
`Page 4
`
`

`

`patent applications. The guide is available either by contacting the USPTO Contact Center at 800—786—91 99. or it
`can be viewed on the "US PTO website at httptffwww.uspto.goviwebiofficesrpacidoc/generalfindexhtml.
`
`For information on preventing theft of your intellectual property (patents. trademarks and copyrights}, you may wish
`to consult the us. Government website, http:iz’www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Government hotline at 1-866-999-HALT (1 866-999-4258).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`QRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 515(k)). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12.
`if a license is desired before the expiration of 8 months from the filing date of the application. If 6 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181 , the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`
`page 3 of 4
`
`Liquidia's Exhibit 1016
`Page 5
`
`Liquidia's Exhibit 1016
`Page 5
`
`

`

`SelecrUSA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The US. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote and facilitate business investment. SelectUSA provides information assistance to the international investor
`community; serves as an ombudsman for existing and potential investors; advocates on behalf of US. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology. manufacture products. deliver services, and grow your business, visit httpflwwwfielectUSAgov or call
`+1-202-482-6800.
`
`page 4 of 4
`
`Liquidia's Exhibit 1016
`Page 6
`
`Liquidia's Exhibit 1016
`Page 6
`
`

`

`PART B - FEEIS} TRANSMITTAL
`
`Complete and send this form, together with applicable. Feats). by mail or fax. or via EFS—Web.
`By mail. send to:
`Mail Stop ISSUE FEB
`Commissioner for Patents
`P.O. Box I450
`Alexandria. Virginia 223134450
`_—_________.__—_..—.————-——————
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE [ifrequiredl Blocks 1 through 5 should be completed where appropriate. All
`lurther correspondence. including the Patent. advance orders and notification of maintenance fees will be tutti led to the current emrespondence address as indicated unless corrected
`below or directed otherwise in Block. 1. b [at s eci Win it new wires ‘tJI'ldEflCE address; untlt'or {b} intlicatin a se arate "FEE ADDRESS" for mnintenamcc l'ec notifications.
`
`Note: A certificate of mailing can only be used for domestic mailings ol‘ the
`Poet's] Transmittal. This certificate cannot he used for any other acconusanying
`papers. Each additional paper. such as an assignment or formal drawing. must
`have its own certificate oi mailing or transmission.
`
`
`
`L‘URREIKT CORRESPONDENCE ADDRESS t Note: In: tilt-cl: I in any change of :ddrcssl
`
`By fax. send to:
`
`(571)-2i3-2885
`
`MUSEUM
`
`7590
`11423
`Foley & Lardner LLP
`fl
`1
`_
`3000 K STREET IN .W.
`SUITE 600
`WASHINGTON. DC 20007-5] 09
`
`Ceflificate of Mailing or Transmission
`I hereby certify that this Fests} Transmittal is being deposited with the United
`States Postal Servrcc with sutltctent postage for first class mail in an envelope
`add:essed to the Mail Stop ISSUE EEE address above, or being transmitted to
`die USP’I'U quFS-Web or by facsimile to {571} 213-2885. on the date below,
`”"1”" "' “mm “5““:
`
`APPLLCATIUN N0.
`
`FILING 1):! IE
`
`
`
`
`
`FlRS‘l' NAMED INVEN TOR
`
`A'l'IICIltNE‘t’ DOCKET NO.
`
`CDNFI RMA'I' ION NO.
`
`
`
`
`
`15l011.999
`
`llEItl l £1016
`
`Horst OLSCl-[EWSKI
`
`{130618-1639
`
`490'!
`
`TITLE 01" INVENTION: TRIZPRUSTINIL ADMINISTRATION BY INHALATION
`
`APPLN. TYPE.
`
`DATE DUE
`
`ENTI'l'Y S'I‘AT'US
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEES} DUE
`
`noupmvisic-nel
`
`UNDISCOINT'ED
`
`$100!}
`
`$0.00
`
`$0.00
`
`51000
`
`OTEWIEOI l?
`
`EWIINER
`
`ARI UNlT
`
`CI A SS—SU BCLASS
`
`SCHMITT, MICHAEL J
`
`16119
`
`5 lr-L I 33000
`
`.
`
`range n correspon once address or In teatton o
`CFR L363}.
`
`IJ Change of correspondence address [or Change of Correspondence
`Address form PT‘Or’Sl-if Ill] attached.
`
`
`'orprtnttngon iepatcnt romp-age.
`st
`
`co Address" ( 'l'
`t l) The. names of up In 3 registered patent attorneys
`._
`
`
`or agents 011. alternatively.
`l
`F016_¥_& Lardnm LLP
`
`[2:] The aortic of a single film (having as n membern
`
`registered attorney or agent) and the. names of up to
`2
`2 registered patent attorneys or agents. If no name is
`IJ "Fee Address" indication (or "Flee Address" Indication form PTO!
`listed. no name will be printed.
`
`SEE-4?; Rev I'll—[)9 or more recent) attached. Use. of a Customer
`Number is r
`aired.
`3. ASSIGN'EE NAME AND RESIDENCE DATA TO BE PRINTED ON TH]; PA'I'ENT (print 01' W1“)
`
`3
`
`11" Ill] itsaignee is identified below. the document must have. been previously
`PLEASE NOTE: Unless an assignee is identified below. on assignee data will emotion the patent.
`recorded, or filed [or recorderio n. as set forth in 3‘! CFR 3.! l and 3'! CFR 3.81M}. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`[B] RESIDENCE: (CITY and STATE 0R COUNTRY)
`
`United Therapeutics Corporation
`Silver Spring, MD
`Please check the appropriate. assignee category or categories {will not he printed on the patent} : 3 Individual 3 Corporation or other private group entity In Government
`4:. Fees submitted:
`Elssue Fee
`UI’ublication Fee t if required)
`jAdvauce Order — it of Copies
`4h. Method of Payment: {Plensefirst‘ reapply wry previously paidfee shown above)
`
`_l Non-electronic payment by credit card (Attach rum PTO-2033)
`IJ Erieltlsntl cheek
`IEI Eleclmnic Payment via tars-web
`
`El The Director is hereby antlmrired to charge the required facts). any deficiency. or credit any overpayment to Deposit Account No. I 9'07‘4 l
`
`5. Change in Entity Status (from status indicated above)
`'3 Applicant certifying micro entity status. See 37 ("fl-“R 1.39
`
`LI Applicant asserting small entity status. See 37 CFR 12?
`
`
`NOTE: Absent a valid certification of Micro Entity Status (see forms PTDISBI 15A and 1513). issue
`fee payment in the micro entity amount will not he accepted at the risk of application abandonmenL
`NOTE: If the application was previously under micro entity status. checking on: box will be taken
`to be a notification of loss of entitlement to micro entity status.
`M Checking this box will be taken to be a notification of loss of entitlement to small or micro
`I3 Applicant Changing to regular untliseountod for! status.
`entity status. as applicable.
`NOTE: This Form must be si net] in accordance with 3? CFR 1.31 and L33. See 3'.’ CFR [.4 for si nature re Ltiretnents and certifications.
`
`
`
`
`JUL 0 2 2019
`Authorized Signature _ {SIMMaabjusl
`35,264
`Stephenie. lVlaebius
`"hyped or printed name Registration No. _
`
`
`
`PTOL-SS Part B (08-13} Approved for use through {HE ”2020
`
`Page '1 of 3
`0MB 0651-6033
`
`US. Patent and Trademark Office; L.__S_ DEPARTMENT OF COMMERCE
`Liquidia's Exhibit 1016
`Page 7
`
`Date
`
`Liquidia's Exhibit 1016
`Page 7
`
`

`

`Electronic Patent Application Fee Transmittal
`
`
`
`Filing Date: 01—Feb-2016
`
`Title of Invention:
`
`TREPROSTINIL ADMINISTRATION BY INHALATION
`
`
`
`First Named Inventormpplicant Name:
`
`Horst OLSCHEWSKI
`
`Attorney Docket Number:
`
`080618-1639
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111(3}
`
`
`
`
`
`
`
`Su b-Total in
`Description USD{$l Fee Code Quantlty Amount
`
`
`
`
`
`Basil: Filing:
`
`
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent~Appeals~and~lnterference:
`
`Post—Allowa nce—and-Post—lssuance:
`
`Liquidia's Exhibit 1016
`Page 8
`
`Liquidia's Exhibit 1016
`Page 8
`
`

`

`.
`
`'
`
`Total in USD (5)
`
`Miscellaneous:
`
`Sub-Total in
`
`Liquidia's Exhibit 1016
`Page 9
`
`Liquidia's Exhibit 1016
`Page 9
`
`

`

`Electronic Acknowledgement Receipt
`
`Application Number:
`
`15011999
`
`International Application Number:
`
`Confirmation Number:
`
`Title of Invention:
`
`TREF‘ROSTINIL ADMINISTRATION BY INHALATION
`
`First Named lnventorlApplicant Name:
`
`Horst OLSCHEWSKI
`
`
`
`
`
`Filer: Stephen Bradford Maebius/Karen Strawderrnan
`
`Filer Authorized By:
`
`Stephen Bradford Maebius
`
`Attorney Docket. Number:
`
`080613—1639
`
`Receipt Date:
`
`02—JUL—201 9
`
`
`
`Filing Date: 01 -F EB-201 6
`
`Time Stamp:
`
`14:43:23
`
`Application Type:
`
`Utility under 35 USC 111(a]
`
`Payment information:
`
`Payment Type
`
`CARD
`
`
`
`RAM confirmation Number
`
`070319lNTEFSW14434400
`
`——
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Liquidia's Exhibit 101 .
`Page 10
`
`Liquidia's Exhibit 1016
`Page 10
`
`

`

`File Listing:
`
`Document
`.
`.
`.
`File SizeiBytes}!
`
`Number Message Digest Document Description File Name
`
`
`150127
`
`Issue Fee Payment {PTOBSB}
`
`=11nilfln1293aii 2 I F1339] 27695 R9FJIM§di
`DBCInu
`
`Warnings:
`
`Information:
`
`Fee Worksheet (SBOfil
`
`fee—infopdf
`
`1 'Ii 3 I £15390! 5 I lL'rIL‘5 I Futidefl IEJcElfuTGJ
`Of-l'iri
`
`Warnings:
`
`Information:
`
`
`
`Total Files Size (in bytes) 180760
`
`
`
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date {see 37 CFR
`1.53{b}-[d} and MPEP 506}, a Filing Receipt [37 CFR 1.54} will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date ofthe application.
`
`National Stage of an International Application under 35 U.S.C. 371
`Ifa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCTIDOIEOIQIB indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Application Filed with the USPTO asa Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP1810}, a Notification of the International Application Number
`and of the International Filing Date [Form PCTIROHOS) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`Liquidia's Exhibit 1016
`Page 11
`
`Liquidia's Exhibit 1016
`Page 11
`
`

`

` DECLARATION [3? CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
`
`PTDrAlAiOi modified)
`
`030613-1539
`
`USING AN APPLICATION DATA SHEET (3? CFR 1.76)
`
`Title of
`nver‘lhon
`TREPROSTINiL ADMINISTRATION EY INHALATION
`l
`.
`
`
`As the below named inventor, I hereby declare that.
`
`This UECI-‘Nfiilfln
`is directed to
`
`E]
`
`E]
`
`The attached anplioaiion. or
`
`United States application or PCT international application number 15i011.999
`filed on EMTZEHS.
`
`The above-identified application was made or authorized to be made by me.
`
`I oeiieve that i am the original inventor or an original joint inventor of a claimed invenlion in the application.
`
`l hereby acknowledge that any willful false statement mace in this declaration is punishable under 18 us C. 1001 by
`fine or imprisonment of not more than (5} years, or both.
`
`WARNING
`
`
`
`Petitionerlapplicant :s cautioned to avoid submitting personal information in documents filed in a patent application that
`may contribute to identity theft. Personal information such as social security numbers, bank account numbers. or credit
`card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is
`never required by the USPTO to suppor. a petition or an application.
`If [his type of personal information is included 'in
`documents submitted to the USPTO, petitionersiapplicants should consider reclaiming such personal information from
`the documents before submitting them to the USPTO. Petitioneriapplicant is advised that the record of a patent
`application is available to the public after publication of the application {unless a non—publication request in compliance
`with 37 CFR 1.213(3) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned
`application may also be available to the public if the application is referenced in a published application or an issued
`patent (see 3? CFR‘ 114). Checks and credit card authorization forms PTO—2038 submitted tor payment purposes are
`not retained in the application file and therefore are not publicly available.
`
`LEGAL NAME OF lNVENTOR
`
`inventor
`Signature:
`
`DatefOptionali;
`
`’4’:
`
`[bl-r11 20”;
`
`Note: An application data sheet {PTOISBTM or equivalent). including naming the enti'e inventive entity. must
`aucom party lnis iorrr- or mu st have been previous); filed Use an additional PTDi'AIAi'm form for each additional
`inventor.
`
`Liquidia's Exhibit 1016
`Page12
`
`Liquidia's Exhibit 1016
`Page 12
`
`

`

`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN
`
`,
`
`080618-1639
`
`APPLICATION USING AN APPLICATION DATA SHEET {3? CFR1.76)
`
` Title of
`
`
`Invention
`TREPROSTINIL ADMINISTRATION BY INHALATION
`
`
`
`
`
`
` This declaration E] The attached application. or
`is directed to:
`
`
`
`>11
`United States application or PCT international application number 151011.999
`filed on 211i20‘l E.
`
`As the below named inventor. I hereby declare that;
`
`
`
`The above-identified application was made or authorized to be made by me
`
`
`
`I believe that I am the original inventor or an original joint inventor oi a claimed invention in the application.
`
`
`
`
`I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 1.2.3.0 1001 by
`fine or imprisonment of not more than {5) years. or both.
`
`
`
`
`Petitioneriapplicant is cautioned to avoid submitting personal information in documents filed in a patent application that
`may contribute to identity theft. Personal information such as social security numbers. bank account numbers. or credit
`
`card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is
`never required by the USPTO to support a petition or an application. it this type of personal information is included in
`
`
`
`
`documents submitted to the USPTO. petitionersrapplicants should consider redacling such personal information from
`
`
`the documents before submitting them to the USPTO. Petitionerrapplicant is advised that the record of a patent
`
`
`application is available to the public after publication of the application (unless a non-publication request in compliance
`
`
`with 37 CFR 1.213(3) is made in the application) or issuance of a patent. Furthermore. the record from an abandoned
`
`
`
`
`application may also be available to the public if the application is referenced in a published application or an issued
`
`
`
`
`
`
`patent (see 3? CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are
`
`
`
`
`not retained in the application file and therefore are not publicly available.
`
`LEGAL NAME OF INVENTOR
`
`WARNING:
`
`1M
`
`Date (Optional): CHI; {20? f:
`
`
`
`
`
`Robert RUSCIGNO
`flat/{K flnfdflz'f'.
`
`inventor:
`Signature:
`
`
`
`
`Note: An application data sheet {PTOISBIM or equivalent). including naming the entire inventive entity, must
`
`accompany this form or must have been previously filed. Use an additional PTOIAIAIUt form for each additional
`inventor.
`
`
`
`4352-?144—81091
`
`Liquidia's Exhibit 1016
`Page 13
`
`Liquidia's Exhibit 1016
`Page 13
`
`

`

`
` DECLARATION [37 CFR 1.63] FOR UTILITY 0R DESIGN
`
`
`080618-1639
`APPLICATION USING AN APPLICATION DATA SHEET (37 (ZFR 1.76)
`
`Title of
`
`
`
`TREPROSTiNIL ADMINISTRATION BY INHALATION
`Invention
`
`
`
`As the below named inventor; i hereby deciare that;
`
`
`
`E
`United States application or PCT international application number 152011.995}
`filed on 2iii’2018_
`
`
`The above-identified application was made or authorized to be made by me.
`
`
`i believe that i am the original inventor or an original joint inventor of a claimed invention in the application.
`
`i hereby acknowledge that any willful false statement made in this declaration is punishable Under 18 U.S.C. 1001 by
`fine or imprisonment of not more than {5) years. or both
`
`[:I
`
`The attached application. or
`
`This declaration
`is directed to:
`
`
`
`WARNING:
`
`
`Petitioneriappiioant is cautioned to avoid submitting personal information in documents filed in a patent application that
`may contribute to identity theft. Personal iniormation such as social security numbers, bank account numbers. or credit
`
`
`card numbers (other than a check or credit card authorization form PTO~2G38 submitted tor payment purposes} is
`never required by the USPTO to support a petition or an application. If this type of personal information is included in
`
`
`documents submitted to the USPTO‘ petitionersiapplicants should consider redacting such personal information from
`the documents before submitting them to the USPTO. Petitionerlapplicant is advised that the record of a patent
`application is available to the public after publication of the application (unless a non-publication request in compliance
`with 37 CFR 1.213(3) is made in the application) or issuance cl a patent Furthermore. the record from an abandoned
`application may also be available to the public it the application is referenced in a published application or an issued
`patent (see 37 CFR 1.14) Checks and credit card authorization forms PTO-2038 submitted for payment purposes are
`not retained in the application tile and therefore are not publicly available.
`
`
`
`
`
`
`
`
` LEGAL NAME OF JN‘JENTOR
`
`
`
`Inventor:
`
`Lewis J. RUBlN
`
`Date (Optionaii:
`
`.3 Z ‘ir kit;
`
`Signature:
`
`
`Note: An application data sheet: (PTOISBI14 or equivalent}, including naming the entire inventive entity, must
`
`
`accompany this form or must have been previously filed. Use an additional PTOMINO'I form for each
`additional inventor.
`
`
`ant-u H.4‘ v-urm .
`
`Liquidia's Exhibit 1016
`Page 14
`
`Liquidia's Exhibit 1016
`Page 14
`
`

`

`DECLARATION (3? CFR 1.63) FOR UTILITY 0R DESIGN
`APPLICATION USING AN APPLICATION DATA SHEET (3? CFR 1.76)
`
`080613-1639
`
`Title of
`TREPRGSTlNIL ADMINlSTRATIDN BY INHALATlGN
`Invention
`
`
`As the oelow named inventor I hereby declare that:
`
`This declaration
`is directed to-
`
`I]
`
`E
`
`The attached application, or
`
`United States application or PCT International application number 15ft)! 1 9.99
`tiled on 2i‘il20’16
`
`The above—identified application was made or authorized to be made by me
`
`i celieve that i am the original inventor or an original joint inventor of a claimed invention in the application.
`
`l hereby acknowledge that any willful false statement made in this declaration Is punishable under 18 USS. 1001 by
`fine or imprisonment of not more than {5} years, or both
`
`WARNING:
`
`Petitioneriapplicant is cautioned to avoid submitting personal infon'nation in documents flIBd in a patent application that
`may contribute to identity theft. Personal information such as social security numbers, bank account numbers or credit
`card Plumbers [other than a check or credit card authorization form PTO-2033 submitted for payment purposes) is
`never required by the USPTO to support a petition or an application. If this type oi personal information is included in
`documents submitted to the USPTO. petitionerslappticants should consider redacting such personal information from
`the documents before submitting them to the USPTO. Petitionerlappiicant is advised that the record of a patent
`application is available to the public after publication of the application tuniess a non~publication request in compliance
`with 3? CFR 1.213ta) is made in the application) or issuance of a patent. Furthermore. the record from an abandoned
`applicatlon may also be available to the public it the application is referenced in a published application or an issued
`patent [see 3? CFR 1.14}. Checks and credit card authorization forms PTO-2038 submitted for payment purposes are
`not retained in the application file and therefore are not publicly available.
`
`
`
`LEGAL NAME OF INVENTOR
`
`-.
`
`inventor:
`
`Werner SEEGE'Fl-‘I
`
`Signature.
`
`it»;
`
`Date iOpiionalli r;
`
`Note' An application data sheet [PTOIS Bi14 or equivalent}. including naming the entire inventive entitt-g must
`accompany this r'orrn or must have been premously filed. Use an additional PTOiAiNDt form for each additional
`inventor.
`
`1852-3144431 09,1
`
`Liquidia's Exhibit 1016
`Page 15
`
`Liquidia's Exhibit 1016
`Page 15
`
`

`

`Do: code 0ch
`Document Description. 0th or declaration tiled
`
`”0!th tor 1.1)
`
`not: ”HURON 0M3 cosmos;
`Anpmved For us
`
`i..t.-S. DEPARTMENT OF COMMERCE
`u 5 F’elur'r and trademark ur-
`Undo: the F‘spe‘wo